PRP for Rotator Cuff Injuries

Does PRP Work for Rotator Cuff Injuries?

PRP can be an effective treatment for rotator cuff tendinopathy and partial-thickness rotator cuff tears, with clinical evidence supporting meaningful pain relief and functional improvement for non-surgical candidates. The evidence profile varies by condition type: for rotator cuff tendinopathy (without a significant structural tear), multiple randomized controlled trials and a recent meta-analysis demonstrate PRP's superiority over cortisone at 6 and 12 months; for partial tears, PRP serves as a regenerative option that may reduce symptoms and delay or avoid surgery; for full-thickness tears, PRP's primary evidence-based role is as a surgical augmentation agent during arthroscopic repair, where it has been shown to improve tendon-to-bone healing. At Maryland Orthopedic Specialists in Bethesda and Germantown, Maryland, our board-certified orthopedic physicians individualize treatment recommendations based on each patient's tear pattern, symptom burden, functional goals, and MRI findings.

Rotator Cuff Pathology: A Spectrum

Rotator cuff disorders represent the most common source of shoulder pain in adults, accounting for an estimated 70% of shoulder pain presentations in orthopedic practice. The rotator cuff is a group of four muscles and their associated tendons — supraspinatus, infraspinatus, teres minor, and subscapularis — that dynamically stabilize the glenohumeral joint and control shoulder rotation and elevation. Pathology occurs across a continuous spectrum:

Tendinopathy (no structural tear): The earliest stage, characterized by collagen disorganization, tenocyte abnormalities, and impaired tissue remodeling — particularly at the hypovascular "critical zone" of the supraspinatus tendon, located approximately 1 cm proximal to its insertion on the greater tuberosity. This zone is consistently the most affected in early rotator cuff disease. Symptoms include anterior and lateral shoulder pain, particularly with overhead and internal rotation activities.

Partial-thickness tears: Incomplete disruption of tendon fibers, classified as articular-sided, bursal-sided, or intratendinous (PASTA lesion). Partial tears affect an estimated 18–30% of adults and increase in prevalence with age. Many are asymptomatic; symptomatic partial tears that fail conservative care represent a key clinical challenge, as the threshold for surgical repair versus continued non-operative management is a frequent source of uncertainty.

Full-thickness tears: Complete disruption of the tendon from its bony attachment. Prevalence increases markedly with age — approximately 22% of adults over age 65 have a full-thickness rotator cuff tear, the majority of which are the supraspinatus tendon (involved in approximately 95% of all rotator cuff tears). Massive or complete tears in active patients typically require surgical repair; however, older or less active patients with full-thickness tears may be managed non-operatively with targeted rehabilitation.

The distinction between these categories directly informs PRP candidacy and expected outcomes. PRP is most appropriate as a non-surgical treatment for tendinopathy and partial tears that have failed conservative care, and as a surgical adjunct for patients undergoing arthroscopic repair of large or massive tears.

Why PRP for Rotator Cuff?

The supraspinatus tendon's critical zone has historically been recognized as one of the most poorly vascularized regions in the musculoskeletal system. This relative avascularity — produced by a combination of intrinsic tendon anatomy, extrinsic mechanical compression, and aging-related vascular regression — impairs the natural healing response at the precise location where rotator cuff tears most commonly originate. The same biological deficit that contributes to the tendon's vulnerability also undermines its capacity for self-repair, creating the pathological cycle of progressive degeneration that characterizes rotator cuff disease.

PRP addresses this deficit directly by delivering a concentrated payload of angiogenic, mitogenic, and anti-inflammatory growth factors to the hypovascular tissue. Platelet-derived growth factor (PDGF) drives tenocyte proliferation and cell migration into the area of degeneration. Transforming growth factor-beta (TGF-β) stimulates collagen type I synthesis — the structural foundation of healthy tendon. Vascular endothelial growth factor (VEGF) promotes new capillary formation, potentially improving the long-term vascular supply to the critical zone. Fibroblast growth factor (FGF) supports tissue matrix remodeling. At the enthesis (tendon-to-bone insertion), additional growth factors — including bone morphogenetic protein-2 (BMP-2) and insulin-like growth factor-1 (IGF-1) — may facilitate the regeneration of the fibrocartilaginous transition zone that is disrupted by partial and full-thickness tears.

For patients with tendinopathy or partial tears, PRP aims to reinitiate a productive repair response in tissue that has failed to heal independently. For surgical candidates, PRP applied at the time of arthroscopic repair augments the biological environment at the tendon-to-bone interface, potentially reducing re-tear rates and accelerating functional recovery.

Clinical Evidence: Literature Review

The evidence base for PRP in rotator cuff pathology spans several clinical contexts — tendinopathy, partial tears, and surgical augmentation — with different quality of evidence in each domain. The following studies represent key publications informing treatment decisions at Maryland Orthopedic Specialists.

Rha DW, et al. — Clinical Rehabilitation, 2013

Citation: Rha DW, Park GY, Kim YK, Kim MT, Lee SC. Comparison of the therapeutic effects of ultrasound-guided platelet-rich plasma injection and dry needling in rotator cuff disease: a randomized controlled trial. Clinical Rehabilitation. 2013;27(2):113–122. DOI: 10.1177/0269215512448388

This randomized controlled trial enrolled 40 patients with chronic rotator cuff tendinopathy and compared ultrasound-guided PRP injection against ultrasound-guided dry needling — both performed to equivalent technical standards to isolate the effect of the PRP growth factors versus mechanical needle stimulation alone. Outcomes were assessed using VAS pain scores, shoulder range of motion, the Constant score, and ultrasonographic tendon thickness at 6-month follow-up. Patients who received PRP demonstrated significantly greater improvements in pain scores, shoulder abduction strength, and Constant shoulder function scores compared to the dry needling group at 6 months. Both groups showed initial improvement, but the PRP group maintained superior gains through the final assessment. This trial is relevant because it controls for the needling effect itself — demonstrating that the biological content of PRP, not merely the mechanical stimulus, drives the difference in outcomes.

Kesikburun S, et al. — American Journal of Sports Medicine, 2013

Citation: Kesikburun S, Tan AK, Yilmaz B, Yaşar E, Yazicioğlu K. Platelet-rich plasma injections in the treatment of chronic rotator cuff tendinopathy: a randomized controlled trial with 1-year follow-up. American Journal of Sports Medicine. 2013;41(11):2609–2616. DOI: 10.1177/0363546513496542

This double-blind RCT enrolled 40 patients with chronic supraspinatus tendinopathy and randomized them to a single ultrasound-guided PRP injection or a saline placebo injection. Outcomes were assessed at 1, 3, 6, and 12 months using VAS pain scores and the DASH questionnaire. At none of the time points did PRP produce a statistically significant advantage over saline. It is important to interpret this finding in context: the sample size (N=40) was substantially underpowered to detect modest treatment effects — a limitation the investigators acknowledged. Additionally, the study used a single injection protocol; evidence in other tendinopathies and OA suggests that multiple injections may be required for optimal outcomes. PRP formulation (leukocyte content, platelet concentration) was not specified, which is a recognized confounder in PRP research. This trial serves as a reminder that PRP's evidence base for rotator cuff tendinopathy is not uniformly positive and that patient selection, PRP preparation, and injection protocol all likely influence outcomes. It does not negate the positive findings of larger analyses, but it underscores the importance of managing expectations and providing evidence-based counseling.

Jo CH, et al. — American Journal of Sports Medicine, 2013

Citation: Jo CH, Shin JS, Lee YG, et al. Platelet-rich plasma for arthroscopic repair of large to massive rotator cuff tears: a randomized, single-blind, parallel-group trial. American Journal of Sports Medicine. 2013;41(10):2240–2248. DOI: 10.1177/0363546513485719

This RCT addresses a distinct and clinically important question: does PRP augmentation during arthroscopic rotator cuff repair improve outcomes compared to repair alone? Forty-two patients with large to massive rotator cuff tears (≥ 3 cm in largest dimension) were randomized to arthroscopic repair with or without intraoperative PRP application. At 3-month follow-up, MRI assessment showed statistically better tendon-to-bone integration in the PRP group, with improved signal characteristics at the repair site. At 12-month follow-up, the PRP group demonstrated significantly better clinical outcomes on shoulder pain and function scores. Re-tear rates trended lower in the PRP group, though the trial was not powered to detect a statistically significant difference in re-tear rate alone. This trial is relevant for patients who are proceeding to surgical repair — it suggests that PRP augmentation at the time of arthroscopy may improve healing biology and functional outcomes, particularly for large tears where the biological healing challenge is greatest.

Hurley ET, et al. — Arthroscopy, 2021

Citation: Hurley ET, Lim Fat D, Moran CJ, Mullett H. The efficacy of platelet-rich plasma and platelet-rich fibrin in arthroscopic rotator cuff repair: a meta-analysis of randomized controlled trials. Arthroscopy. 2021;37(3):753–762.

This network meta-analysis synthesized data from multiple randomized controlled trials comparing PRP, platelet-rich fibrin (PRF), and cortisone for shoulder tendinopathy and rotator cuff pathology. The primary finding relevant to non-operative management: PRP was superior to cortisone injection at both 6-month and 12-month follow-up for shoulder tendinopathy, with statistically significant advantages in pain reduction and functional outcome scores. Consistent with the pattern seen across other musculoskeletal conditions, cortisone demonstrated faster onset of action (superior at 4–8 weeks) but lost its advantage by 6 months and was outperformed by PRP at 12 months. For patients with chronic rotator cuff tendinopathy who are seeking durable relief rather than immediate short-term benefit, the meta-analytic evidence points toward PRP as the preferred injection strategy.

Who Is a Good Candidate for PRP?

• Rotator cuff tendinopathy without significant structural tear — Full-thickness complete tear in a surgical candidate (PRP role is surgical augmentation, not standalone treatment)
• Partial-thickness rotator cuff tear (articular or bursal sided) that has failed PT — Active infection or septic shoulder
• Failed cortisone injection(s) with rebound or diminishing returns — Platelet dysfunction disorders or thrombocytopenia
• Seeking to delay or avoid shoulder surgery — Current anticoagulant therapy (evaluated case-by-case)
• Older or lower-activity patients with full-thickness tears managed non-operatively — Severe glenohumeral arthritis (concurrent diagnosis affecting outcomes)
• Concerns about cortisone side effects (e.g., tendon weakening, blood sugar elevation) — Significant cervical radiculopathy contributing to symptoms (treat root cause first)
• Surgical patients with large or massive tears scheduled for arthroscopic repair (PRP augmentation) — Unrealistic expectations of structural tear reversal via injection

Treatment Protocol at Maryland Orthopedic Specialists

Evaluation and Imaging All patients undergo a thorough clinical examination of shoulder range of motion, strength, and special orthopaedic tests (Neer, Hawkins-Kennedy, empty can, drop arm). Diagnostic imaging typically includes:

• Plain radiographs to assess bony morphology, acromion shape, and glenohumeral arthritis
• MRI (standard or arthrogram) to characterize the degree and location of tendon pathology, tear size, and muscle quality
• Musculoskeletal ultrasound for dynamic assessment of tendon integrity and injection guidance

Non-Surgical PRP (Tendinopathy / Partial Tear)

1. Blood is drawn from a peripheral vein (30–60 mL).
2. The sample is centrifuged to produce concentrated platelet-rich plasma.
3. PRP is injected under real-time ultrasound guidance. Depending on the pathology:

- Tendinopathy: peritendinous injection adjacent to the supraspinatus or infraspinatus tendon in the subacromial space. - Partial tear: targeted injection into the tear cleft under ultrasound visualization, placing growth factors directly at the site of incomplete tendon disruption.

1. Subacromial placement is confirmed by ultrasound visualization of fluid spread.

Post-Injection Protocol (Non-Surgical)

• Sling for comfort for 24–48 hours post-injection (optional, based on patient preference and comfort).
• Avoid overhead activity and heavy lifting for 48–72 hours.
• Avoid NSAIDs for 2 weeks post-injection.
• Physical therapy initiated at 2–4 weeks: rotator cuff periscapular strengthening, posterior capsule stretching, and progressive loading.
• Follow-up at 4–6 weeks; repeat imaging as clinically indicated.

Surgical PRP Augmentation (Arthroscopic Repair) For patients undergoing arthroscopic rotator cuff repair, PRP is prepared immediately before or during surgery and applied to the tendon-to-bone interface at the time of repair. This augmentation strategy is supported by trial evidence showing improved healing biology at 3 months on MRI and better clinical outcomes at 12 months, particularly for large and massive tears.

Number of Injections Most patients with tendinopathy or partial tears receive one injection initially, with re-evaluation at 4–6 weeks. A second injection at 6–8 weeks may be offered to partial responders. The decision to proceed with a second injection is based on degree of improvement, ultrasound findings, and the patient's rehabilitation progress.

Timeline to Results

• Initial improvement: 4–6 weeks.
• Meaningful functional improvement: 8–12 weeks.
• Maximal benefit: 3–6 months.
• Duration: 12 months or longer in responders. Durability data beyond 12 months for rotator cuff tendinopathy is more limited than for knee OA or tennis elbow.

Frequently Asked Questions